{"id":"cyc","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Hemorrhagic cystitis"},{"rate":null,"effect":"Infertility"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":{"setId":"8833d6e6-33ab-4ea9-b78f-3ec30a904ef8","title":"LOKELMA (SODIUM ZIRCONIUM CYCLOSILICATE) POWDER, FOR SUSPENSION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is a nitrogen mustard alkylating agent that forms covalent bonds with DNA, causing cross-linking and strand breaks that prevent cell division. It is a prodrug requiring hepatic activation and is used primarily in sarcoma and other malignancies. The drug is non-cell-cycle specific and has immunomodulatory effects in addition to direct cytotoxic activity.","oneSentence":"CYC is a cyclophosphamide-based chemotherapy agent that alkylates DNA to inhibit cancer cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:35.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sarcoma (various histologies)"},{"name":"Soft tissue sarcoma"},{"name":"Bone sarcoma"}]},"trialDetails":[{"nctId":"NCT05567198","phase":"","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-03-03","conditions":"Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)","enrollment":100},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT03936829","phase":"NA","title":"Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-04-28","conditions":"Lipodystrophy Acquired, Type1diabetes","enrollment":10},{"nctId":"NCT05770349","phase":"","title":"Ultrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure","status":"RECRUITING","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2023-03-31","conditions":"Heart Failure, Coronary Artery Disease","enrollment":45},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT05679401","phase":"PHASE3","title":"A Study With Imlifidase in Anti-GBM Disease","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-22","conditions":"Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome","enrollment":50},{"nctId":"NCT06152172","phase":"PHASE1","title":"CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Porter","startDate":"2024-08-05","conditions":"Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis","enrollment":24},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06451159","phase":"PHASE1","title":"A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bruce Cree","startDate":"2024-06-20","conditions":"Progressive Multiple Sclerosis","enrollment":10},{"nctId":"NCT07343661","phase":"PHASE4","title":"Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA","status":"ENROLLING_BY_INVITATION","sponsor":"Azienda Ospedaliero Universitaria di Cagliari","startDate":"2025-10-17","conditions":"EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma","enrollment":90},{"nctId":"NCT06429449","phase":"PHASE1","title":"Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-07-21","conditions":"Leukemia, Myeloid Leukemia, Monocytic Leukemia","enrollment":30},{"nctId":"NCT07125404","phase":"NA","title":"Low-Level Laser Auriculotherapy in the Treatment of Myogenic Temporomandibular Disorders and Anxiety","status":"NOT_YET_RECRUITING","sponsor":"Quiropraxia y Equilibrio","startDate":"2025-09-01","conditions":"Temporomandibular Disorder, Anxiety State","enrollment":32},{"nctId":"NCT07056790","phase":"PHASE1, PHASE2","title":"Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-05-15","conditions":"Prostate CA","enrollment":40},{"nctId":"NCT07026578","phase":"","title":"Unravelling the Role of Apoptosis in Platelets Biogenesis Through the Study of the Thrombocytopenia THC4","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2024-06-18","conditions":"Thrombocytopenia, Isolated, Thrombocytopenia 4, CYCS MUTATION- ASSOCIATED THROMBOCYTOPENIA THC4","enrollment":38},{"nctId":"NCT06384976","phase":"PHASE2","title":"KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyverna Therapeutics","startDate":"2024-09-20","conditions":"Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis","enrollment":120},{"nctId":"NCT06680349","phase":"PHASE4","title":"Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2022-12-01","conditions":"Fibrillary Glomerulonephritis","enrollment":21},{"nctId":"NCT02440373","phase":"","title":"Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-03","conditions":"Trauma, Blunt Injury, Blunt Trauma","enrollment":12},{"nctId":"NCT00103792","phase":"PHASE3","title":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2004-12","conditions":"Wegener's Granulomatosis, Vasculitis","enrollment":84},{"nctId":"NCT01895244","phase":"PHASE2","title":"Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2012-09","conditions":"Scleroderma, Cardiac Involvement, Autologous Stem Cell Transplantation","enrollment":44},{"nctId":"NCT02684708","phase":"PHASE3","title":"Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Giessen","startDate":"2015-10-01","conditions":"Classical Hodgkin Lymphoma","enrollment":2200},{"nctId":"NCT01088750","phase":"PHASE4","title":"Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Christine Mauz-Körholz","startDate":"2009-11-01","conditions":"Lymphoma","enrollment":225},{"nctId":"NCT06167174","phase":"","title":"Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2023-12-05","conditions":"Lupus Nephritis","enrollment":100},{"nctId":"NCT03539497","phase":"","title":"Prognostic Value of Plasma Mitochondrial DNA and Cytochrome C After Cardiac Arrest","status":"UNKNOWN","sponsor":"University Medical Centre Ljubljana","startDate":"2019-01-08","conditions":"Cardiac Arrest","enrollment":87},{"nctId":"NCT03096275","phase":"PHASE3","title":"Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis","status":"COMPLETED","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2017-03-16","conditions":"Takayasu Arteritis","enrollment":138},{"nctId":"NCT03345810","phase":"PHASE2","title":"Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2017-12-14","conditions":"Carcinoma, Non-Small-Cell Lung, Metastatic Lung Cancer, Non Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT02997423","phase":"","title":"Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2016-11-30","conditions":"Glioblastoma","enrollment":153},{"nctId":"NCT02727387","phase":"PHASE2","title":"Protocol for the Treatment of Metastatic Ewing Sarcoma","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2009-06-01","conditions":"Ewing's Sarcoma (ES)","enrollment":155},{"nctId":"NCT05495893","phase":"PHASE4","title":"MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN","status":"UNKNOWN","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2022-07-25","conditions":"Mycophenolate Mofetil, Cyclophosphamide, Lupus Nephritis","enrollment":224},{"nctId":"NCT02460588","phase":"PHASE3","title":"Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":120},{"nctId":"NCT04125069","phase":"","title":"Role of Mitochondrial Dysfunction in the Occurrence of Acute Kidney Injury (AKI) in Postoperative Cardiac Surgery","status":"COMPLETED","sponsor":"University Hospital Center of Martinique","startDate":"2019-10-02","conditions":"Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery Requiring Extracorporeal Circulation","enrollment":27},{"nctId":"NCT02505425","phase":"NA","title":"ENABLE CHF-PC (Comprehensive Heartcare For Patients and Caregivers)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-11-30","conditions":"Heart Failure","enrollment":573},{"nctId":"NCT05195086","phase":"","title":"A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt","status":"COMPLETED","sponsor":"Nada Magdy Mansour","startDate":"2018-07-01","conditions":"Lupus Nephritis","enrollment":122},{"nctId":"NCT02106312","phase":"PHASE2","title":"Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2010-12-15","conditions":"Myxoid Liposarcoma of Soft Tissue","enrollment":80},{"nctId":"NCT04802785","phase":"PHASE2, PHASE3","title":"The Impact of Air Travel on Passenger Cognitive Functions","status":"UNKNOWN","sponsor":"Dinara Zhumanbayeva","startDate":"2021-06","conditions":"Air Travel","enrollment":50},{"nctId":"NCT03177447","phase":"NA","title":"ENABLE: CHF-PC (Comprehensive Heartcare For Patients and Caregivers)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2013-07-01","conditions":"Heart Failure, Congestive","enrollment":62},{"nctId":"NCT02370550","phase":"PHASE4","title":"Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":"Sjogren's Syndrome","enrollment":240},{"nctId":"NCT00433459","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Christine Mauz-Körholz","startDate":"2007-01","conditions":"Lymphoma","enrollment":2134},{"nctId":"NCT02046070","phase":"PHASE2","title":"Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-03-05","conditions":"Multiple Myeloma","enrollment":148},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":"Lupus Nephritis","enrollment":120},{"nctId":"NCT03200002","phase":"PHASE2","title":"Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis","status":"COMPLETED","sponsor":"Chitwan Medical College","startDate":"2014-01-01","conditions":"To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients","enrollment":49},{"nctId":"NCT01257802","phase":"PHASE3","title":"GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases","status":"TERMINATED","sponsor":"Joseph Mccune","startDate":"2011-05","conditions":"Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System","enrollment":14},{"nctId":"NCT00482911","phase":"PHASE2","title":"Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2007-04","conditions":"Intraocular Melanoma, Malignant Conjunctival Neoplasm","enrollment":12},{"nctId":"NCT01050439","phase":"PHASE2","title":"Unrelated Donor Transplant for Malignant and Non-Malignant Disorders","status":"TERMINATED","sponsor":"Columbia University","startDate":"2002-11","conditions":"Leukemia, Lymphoma, Bone Marrow Failure Syndromes","enrollment":22},{"nctId":"NCT01072773","phase":"PHASE2","title":"Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-03","conditions":"Primary Systemic Amyloidosis","enrollment":2},{"nctId":"NCT02027220","phase":"PHASE2","title":"Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2013-12","conditions":"Myeloma, Bortezomib, Cyclophosphamide","enrollment":60},{"nctId":"NCT01245621","phase":"NA","title":"Study of Palliative Care Intervention for Advanced Cancer Patients and Their Caregivers -Educate Nurture Advise Before Life Ends (ENABLE III)","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2010-10","conditions":"Advanced Cancer","enrollment":360},{"nctId":"NCT01646736","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2012-07","conditions":"Nephritis, Lupus","enrollment":130},{"nctId":"NCT01207297","phase":"PHASE1","title":"Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2003-03","conditions":"SLE, Lupus Nephritis, Renal Insufficiency","enrollment":40},{"nctId":"NCT00869765","phase":"PHASE2","title":"Transcranial Direct Current Stimulation (tDCS) Augmentation by D-Cycloserine as a Treatment for Depression","status":"COMPLETED","sponsor":"The University of New South Wales","startDate":"2009-04","conditions":"Major Depressive Disorder, Bipolar Disorder","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2809,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyclophosphamide","huanlinxianan"],"phase":"marketed","status":"active","brandName":"CYC","genericName":"CYC","companyName":"Italian Sarcoma Group","companyId":"italian-sarcoma-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CYC is a cyclophosphamide-based chemotherapy agent that alkylates DNA to inhibit cancer cell proliferation. Used for Sarcoma (various histologies), Soft tissue sarcoma, Bone sarcoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}